SynthesisPloS one2016

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis.

Xuelei Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.